These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prevention of hemolytic transfusion reactions with intravenous immunoglobulin prophylaxis in U- patients with anti-U. Win N; Almusawy M; Fitzgerald L; Hannah G; Bullock T Transfusion; 2019 Jun; 59(6):1916-1920. PubMed ID: 30861151 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis]. Cortey A; Elzaabi M; Waegemans T; Roch B; Aujard Y Arch Pediatr; 2014 Sep; 21(9):976-83. PubMed ID: 25125032 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Whole-Blood Exchange Transfusion in Refractory Severe Autoimmune Haemolytic Anaemia Secondary to Systemic Lupus Erythematosus: A Real-World Observational Retrospective Study. Jiang Y; Zhao HJ; Luo H; Li BJ; Zhang ZM; Zhao LD; Zuo XX Front Immunol; 2022; 13():861719. PubMed ID: 35757744 [TBL] [Abstract][Full Text] [Related]
6. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Michelis FV; Branch DR; Scovell I; Bloch E; Pendergrast J; Lipton JH; Cserti-Gazdewich CM Transfusion; 2014 Mar; 54(3):681-90. PubMed ID: 23829192 [TBL] [Abstract][Full Text] [Related]
7. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion. Weinstock C; Möhle R; Dorn C; Weisel K; Höchsmann B; Schrezenmeier H; Kanz L Transfusion; 2015 Mar; 55(3):605-10. PubMed ID: 25251967 [TBL] [Abstract][Full Text] [Related]
8. Autoantibody formation after alloimmunization inducing bystander immune hemolysis. Mota M; Bley C; Aravechia MG; Hamerschlak N; Sakashita A; Kutner JM; Castiho L Immunohematology; 2009; 25(1):9-12. PubMed ID: 19856726 [TBL] [Abstract][Full Text] [Related]
9. [Meta analysis of the effect of immunoglobulin infusion on neonatal isoimmune hemolytic disease caused by blood group incompatibility]. Li ZH; Wang J; Chen C Zhonghua Er Ke Za Zhi; 2010 Sep; 48(9):656-60. PubMed ID: 21092522 [TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. Miqdad AM; Abdelbasit OB; Shaheed MM; Seidahmed MZ; Abomelha AM; Arcala OP J Matern Fetal Neonatal Med; 2004 Sep; 16(3):163-6. PubMed ID: 15590442 [TBL] [Abstract][Full Text] [Related]
11. Transfusions of least-incompatible blood with intravenous immunoglobulin plus steroids cover in two patients with rare antibody. Win N; Needs M; Thornton N; Webster R; Chang C Transfusion; 2018 Jul; 58(7):1626-1630. PubMed ID: 29732576 [TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Nasseri F; Mamouri GA; Babaei H Saudi Med J; 2006 Dec; 27(12):1827-30. PubMed ID: 17143357 [TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Figueras-Aloy J; Rodríguez-Miguélez JM; Iriondo-Sanz M; Salvia-Roiges MD; Botet-Mussons F; Carbonell-Estrany X Pediatrics; 2010 Jan; 125(1):139-44. PubMed ID: 19948572 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Mair B; Benson K Transfusion; 1998 Jan; 38(1):51-5. PubMed ID: 9482394 [TBL] [Abstract][Full Text] [Related]
17. Anti-A and anti-B: what are they and where do they come from? Branch DR Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of Therapeutic Efficacy for Neonatal ABO Hemolytic Disease Treated with Intravenous Immunoglobin G by Different Modes of Administration]. Liu YF; Zou CC; Yang HQ; Lou LJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1842-1845. PubMed ID: 28024505 [TBL] [Abstract][Full Text] [Related]
20. Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review. McCullagh J; Cardigan R; Brunskill SJ; Bullock T; Doree C; Estcourt L; Huish S; Sandercock J; Green L Blood Rev; 2022 Nov; 56():100989. PubMed ID: 35871104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]